Trevi Therapeutics, Inc.TRVINASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank89
3Y CAGR+19.1%
5Y CAGR+8.4%
Year-over-Year Change
Research and development spending
3Y CAGR
+19.1%/yr
vs +9.0%/yr prior
5Y CAGR
+8.4%/yr
Recent acceleration
Acceleration
+10.1pp
Accelerating
Percentile
P89
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $33.48M | -15.0% |
| 2024 | $39.38M | +66.3% |
| 2023 | $23.68M | +19.4% |
| 2022 | $19.83M | -13.7% |
| 2021 | $22.98M | +2.9% |
| 2020 | $22.33M | +15.5% |
| 2019 | $19.34M | +37.4% |
| 2018 | $14.07M | +130.9% |
| 2017 | $6.09M | -11.8% |
| 2016 | $6.91M | - |